Streetbeat News

Products Services

ARWR

Arrowhead Pharmaceuticals has filed for regulatory clearance to start a Phase 1/2a trial for ARO-INHBE, an RNAi therapeutic for obesity. The trial will assess the safety and efficacy of ARO-INHBE alone and in combination with tirzepatide. Arrowhead plans to file for another trial for ARO-ALK7 by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:31 am

GE

MSFT

GE Aerospace has partnered with Microsoft to implement the AI Wingmate platform, powered by Azure AI, to enhance productivity and innovation among its 52,000 employees. This collaboration aims to improve safety, sustainability, and supply chain efficiency in the aerospace industry.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:21 am

KMDA

Kamada Ltd. has expanded its US plasma operations by opening a new plasma collection center in Houston, TX, and plans to submit for FDA approval. The center is expected to significantly increase Kamada's plasma collection capacity and contribute to its revenue growth.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:19 am

MMA

Alta Global Group (NYSE:MMA) partners with UFC Gym Group to expand globally, targeting $7M annual revenue. The partnership will integrate Alta's Warrior Training Program and mobile marketing platform into UFC Gym's network, starting in California in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:16 am

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) has published research demonstrating that its Pressure-Enabled Drug Delivery (PEDD) method significantly improves the delivery of glass microspheres into liver tumors compared to conventional methods. The study, conducted on a porcine liver tumor model, shows enhanced penetration and potential for more effective cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:14 am

INDV

MRNA

PGNY

The article highlights three oversold health care stocks with potential for growth: Progyny Inc, Indivior PLC, and Moderna Inc. These stocks have RSI values below 30, indicating they may be undervalued. Progyny faced a client termination, Indivior updated on a study, and Moderna received vaccine approval in Canada.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 11:13 am

OFIX

Orthofix Medical Inc. (NASDAQ:OFIX) presented new spinal fusion products and data at the NASS Annual Meeting, showcasing innovations like the SpinalStim™ device and OsteoStrand™ Plus C graft. These advancements highlight Orthofix's commitment to improving spinal fusion outcomes.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:10 am

BABA

LI

NVDA

PGJ

Alibaba's cloud computing unit partners with Nvidia to enhance autonomous driving for Chinese automakers amid U.S. semiconductor sanctions. The collaboration integrates Alibaba's language models with Nvidia's platforms, showcasing advancements at the Apsara Conference.

Portfolio Pulse from Anusuya Lahiri

September 23, 2024 | 11:08 am

QURE

uniQure's AMT-191, a gene therapy for Fabry disease, has received Orphan Drug Designation from the FDA. This status supports uniQure's ongoing Phase I/IIa trial and offers incentives like tax credits and market exclusivity upon approval.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:07 am

MIND

MIND Technology's Seamap unit has secured a $5.1 million order for its GunLink source controller, bringing total orders to $7.9 million since July 31, 2024. The company anticipates strong demand and a robust backlog, with deliveries extending into the next fiscal year.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:05 am